Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Hits New 12-Month High – What’s Next?

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high during mid-day trading on Monday. The company traded as high as $51.05 and last traded at $51.05, with a volume of 100 shares traded. The stock had previously closed at $46.00.

Analyst Ratings Changes

Several analysts have recently commented on the company. Pareto Securities raised Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday, October 27th. HC Wainwright reiterated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Wednesday, October 28th. Nordea Equity Research downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $18.17 billion, a PE ratio of 25.40 and a beta of 0.48. The stock’s fifty day simple moving average is $45.82 and its 200-day simple moving average is $44.43.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options.

Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.

The company was formed in 2010 when Biovitrum acquired Swedish Orphan and adopted the Swedish Orphan Biovitrum name.